167 related articles for article (PubMed ID: 37752023)
21. The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer.
Celik M; Bulbul BY; Ayturk S; Durmus Y; Gurkan H; Can N; Tastekin E; Ustun F; Sezer A; Guldiken S
Med Glas (Zenica); 2020 Feb; 17(1):30-34. PubMed ID: 31994851
[TBL] [Abstract][Full Text] [Related]
22. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
[TBL] [Abstract][Full Text] [Related]
23. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of multi-genic assay in identifying aggressive papillary thyroid carcinoma.
Tang L; Shu X; Hu D; Deng C; Ren H; Su X
Am J Otolaryngol; 2022; 43(5):103563. PubMed ID: 35961219
[TBL] [Abstract][Full Text] [Related]
25. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
26. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
[TBL] [Abstract][Full Text] [Related]
27. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].
Wang J; Liu LT; Cui D; He L; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):288-292. PubMed ID: 30955264
[No Abstract] [Full Text] [Related]
28. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
[TBL] [Abstract][Full Text] [Related]
29. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
30. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
31. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
[TBL] [Abstract][Full Text] [Related]
32. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
[TBL] [Abstract][Full Text] [Related]
33. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
[TBL] [Abstract][Full Text] [Related]
34. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
35. A mutation panel comprising BRAF
Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
[TBL] [Abstract][Full Text] [Related]
36. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
37. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Xing M; Alzahrani AS; Carson KA; Shong YK; Kim TY; Viola D; Elisei R; Bendlová B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Clifton-Bligh R; Tallini G; Holt EH; Sýkorová V
J Clin Oncol; 2015 Jan; 33(1):42-50. PubMed ID: 25332244
[TBL] [Abstract][Full Text] [Related]
38. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
[TBL] [Abstract][Full Text] [Related]
39. [Correlation between BRAF
Zhou B; Hei H; Li YQ; Zhang DY; Wang DQ; Qin JW
Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(14):1060-1063. PubMed ID: 37032157
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF
Poyrazoğlu Ş; Bundak R; Baş F; Yeğen G; Şanlı Y; Darendeliler F
J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):185-193. PubMed ID: 28077340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
